What you probably already know: Single or unemployed women on GLP drugs are doing more than just losing weight. A new working paper from the National Bureau of Economic Research, authored by Harvard Professor Rebecca Diamond, finds that weight loss from GLP-1 medications is linked to meaningful shifts in women’s economic and social outcomes, especially for those who are single or unemployed. However, married women didn’t see changes in relationship status and employed women didn’t receive promotions. But for those on the margins of the labor market and the dating pool, the implications were significant.
Why it matters: The clearest shifts show up in two places: work and marriage. The biggest is in the so-called "marriage market," a term often used by economists who study how people choose life partners. Among single women who started treatment, the likelihood of getting married or moving in with a partner increased by 18.3%. After about 18 months on a GLP-1 medication, that climbed to 28.6%. The economic effects were almost as striking for employed women. Starting GLP-1 treatment was linked to a 13% increase in employment. At 18 months that figure more than doubled. Women who found jobs also worked nearly 10 more hours per week on average.
What it means: The paper, “GLP-1 Weight Loss and the Female Obesity Penalty,” focused on women between the ages of 25 and 61 and is perhaps the first research on GLP-1 drugs to reconfirm earlier conclusions that weight affects outcomes in ways that go beyond health. Diamond’s study found that across women aged 25 to 61, GLP-1 use was associated with weight loss of 1.4 to 2.5 BMI points early on, increasing to 2.7 to 4.2 points after 18 months. The study is consistent with previous studies prior to the GLP-1 craze that found that “heavier women earn less, work less and are less likely to marry or cohabit.”
What happens next: Diamond notes that sociologists and economists have long documented that heavier women face severe penalties in both romance and the workplace. Notably, that penalty doesn’t apply equally to overweight men. The research underscores a sobering reality that, despite decades of body-positivity campaigns, deep-seated visual stigmas continue to dictate economic and social mobility for women based on size. The new research doesn’t claim weight loss “fixes” anything, but, as Diamond writes, “Body weight can matter because it affects health, mobility, productivity, confidence, or because other people attach penalties to a visible trait. This pattern helps interpret the female obesity penalty.”
Tomorrow: The body-image implications of GLP-1 drugs.
